
Non-Sponsored Content
CARDIOVASCULAR DISEASE
Registry data shows early and large LDL reductions are associated with lowest post-MI cardiovascular event rates
Medical writer: Kirsty LEE | Last updated: 10th February 2021 | In: -, Cardiovascular
Article Keywords
atherosclerotic cardiovascular disease, cholesterol, hypercholesterolemia, LDL-C, myocardial infarction, registry
Evidence in recent years has shown that the lower the low-density lipoprotein cholesterol (LDL-C) levels, the lower the risk of future cardiovascular events.1Mach F et al. Eur Heart J. 2020;41(1):111-188.The 2019 ESC/EAS guidelines for the management of dyslipidaemias recommend very-high-risk cardiovascular patients to have an LDL-C reduction of ≥50% from baseline, and an LDL-C goal of <1.4 mmol/L (<55mg/dL).1Mach F et al. Eur Heart J. 2020;41(1):111-188. Very-high-risk patients include those with documented atherosclerotic cardiovascular disease, including a history of previous myocardial infarction (MI).1Mach F et al. Eur Heart J. 2020;41(1):111-188.
The SWEDEHEART registry is a Swedish nationwide MI registry that records the patient characteristics, medication, outcomes, and related interventions and preventions.2Schubert J et al. Eur Heart J. 2021;42(3):243-252. All patients with an MI to any coronary care unit in Sweden are admitted to the registry.2Schubert J et al. Eur Heart J. 2021;42(3):243-252. The analysis included patients with an MI admitted between January 2006 and December 2016 who were between the ages of 30 and 75.2Schubert J et al. Eur Heart J. 2021;42(3):243-252.
A total of 40,607 MI patients were included in the analysis, with a median follow-up of 3.8 years.2Schubert J et al. Eur Heart J. 2021;42(3):243-252. Median LDL-C at the time of the index event was 3.1 mmol/L in the overall population, and 3.4 mmol/L for statin-naïve patients, and 2.2 mmol/L for patients receiving statins.2Schubert J et al. Eur Heart J. 2021;42(3):243-252. The median LDL-C change was a 1.2 mmol/L reduction, with the largest mean LDL-C reductions being achieved in statin-naïve patients (mean reduction of 1.7 mmol/L).2Schubert J et al. Eur Heart J. 2021;42(3):243-252.
During the follow-up period, 7% patients died from any cause, 7% experienced a recurrent MI, and 11% had a major adverse cardiovascular event (MACE).2Schubert J et al. Eur Heart J. 2021;42(3):243-252. Patients with a larger LDL-C reduction (75th percentile with 1.85 mmol/L) had a lower risk of all outcomes compared to those with smaller LDL-C reductions (25th percentile with 0.36 mmol/L).2Schubert J et al. Eur Heart J. 2021;42(3):243-252. The reduction in hazard ratio was linear across the interquartile range of LDL-C reduction for MACE, all-cause mortality, and MI.2Schubert J et al. Eur Heart J. 2021;42(3):243-252. For every 1 mmol/L reduction in LDL-C, there was a ~25% relative event rate reduction in major vascular events.2Schubert J et al. Eur Heart J. 2021;42(3):243-252.
The results of this analysis of the SWEDEHEART registry demonstrate that early LDL-C reduction after MI is associated with lower incidence and greater risk reduction of MACE, all-cause mortality, cardiovascular mortality and MI.2Schubert J et al. Eur Heart J. 2021;42(3):243-252. The relationship between LDL-C and event rate reduction was linear, echoing the Cholesterol Treatment Trialists’ Collaboration meta-analysis of statins published in 2010.3Cholesterol Treatment Trialists’ (CTT) Collaboration et al. Lancet Lond Engl. 2010;376(9753):1670-1681.
Reference
- Mach F et al. Eur Heart J. 2020;41(1):111-188.
- Schubert J et al. Eur Heart J. 2021;42(3):243-252.
- Cholesterol Treatment Trialists’ (CTT) Collaboration et al. Lancet Lond Engl. 2010;376(9753):1670-1681.
Newsletter Sign-Up
Do you like our content? Subscribe to our non-intrusive newsletter today! We promise we won’t be spammy.
Newsletter Sign-Up
YOU MAY ALSO LIKE




Disclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2021 MediPaper Medical Communications Ltd. – Registry data shows early and large LDL reductions are associated with lowest post-MI cardiovascular event rates
YOU MAY ALSO LIKE
© Copyright 2021 MediPaper Medical Communications Ltd. – Registry data shows early and large LDL reductions are associated with lowest post-MI cardiovascular event rates
The evolution of hypertension management
COVID-19 impacting regular patient care for cardiovascular diseases
SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy
Data for safe and effective use of evolocumab in paediatric familial hypercholesterolaemia
Psoriasis biologics may help reduce coronary plaque
Ticagrelor may not confer post-MI benefits to elderly patients
Evidence of SARS-CoV2 in heart cells
Risk of thrombosis with SARS-CoV-2 infection
Class effect of SGLT2 inhibitors on heart failure reduction solidified with dapagliflozin and empagliflozin results
Potential protective effects of the influenza vaccine on cardiovascular outcomes in high-risk populations
Highlights of the 8th Asia Pacific Symposium on Cerebrovascular Disease
I-O in Special Populations: Chronic Viral Hepatitis Carriers
Transcatheter aortic valve replacement reduces severe aortic stenosis in real-world study
Transcatheter- vs surgical aortic valve replacement in high-risk patients: 5-years survival
Anti-coagulation: impact on long-term mortality and early valve dysfunction
Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety
Febuxostat prevents CV events in hyperuricaemia patients
Standard- and low-dose rivaroxaban in Asians with AF: Effectiveness and Safety
ASCO16 Nivolumab (Opdivo©) Data
ACC2016: 8½ Important Cardiology Lessons Learned